<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Acrivon Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Acrivon Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 20:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/acrivon-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835423c78dffbe2df0e131a.webp</url>
<title>Acrivon Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Acrivon to Highlight Preclinical Data with Three Posters at AACR Demonstrating Strong ACR-368 and ACR-2316 Synergies with Immune Checkpoint Inhibitors and ADC Payloads, Revealing Broad Clinical Development Opportunities</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-to-highlight-preclinical-data-with-three-posters-at-aacr-demonstrating-strong-acr-368-and-acr-2316-synergies-with-immune-checkpoint-inhibitors-and-adc-payloads-revealing-broad-clinical-development-opportunities</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-to-highlight-preclinical-data-with-three-posters-at-aacr-demonstrating-strong-acr-368-and-acr-2316-synergies-with-immune-checkpoint-inhibitors-and-adc-payloads-revealing-broad-clinical-development-opportunities</guid>
<pubDate>Fri, 17 Apr 2026 20:00:00 GMT</pubDate>
<description>Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 (Topo 1) inhibition Data supports potential for frontline clinical combinations of ACR-368 and ACR-2316 with immune checkpoint inhibitors and of ACR-368 with Topo 1 antibody-drug conjugates (ADCs) WATERTOWN, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq:</description>
</item>
<item>
<title>Acrivon Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-recent-business-highlights</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial</description>
</item>
<item>
<title>Acrivon Therapeutics to Present Pre-Clinical AP3 Data at the 2026 AACR Annual Meeting Revealing Strong Synergy of ACR-368 with ADC Topo 1 Inhibitor Payloads and of both ACR-368 and ACR-2316 with Immune Checkpoint Inhibitors</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-to-present-pre-clinical-ap3-data-at-the-2026-aacr-annual-meeting-revealing-strong-synergy-of-acr-368-with-adc-topo-1-inhibitor-payloads-and-of-both-acr-368-and-acr-2316-with-immune-checkpoint-inhibitors-1</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-to-present-pre-clinical-ap3-data-at-the-2026-aacr-annual-meeting-revealing-strong-synergy-of-acr-368-with-adc-topo-1-inhibitor-payloads-and-of-both-acr-368-and-acr-2316-with-immune-checkpoint-inhibitors-1</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly</description>
</item>
<item>
<title>Acrivon Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage</description>
</item>
<item>
<title>Key Opinion Leader (KOL) Panel to Discuss Acrivon’s ACR-368 Endometrial Cancer (EC) Trial during the 2026 European Society of Gynecological Oncology (ESGO) Congress</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/key-opinion-leader-kol-panel-to-discuss-acrivons-acr-368-endometrial-cancer-ec-trial-during-the-2026-european-society-of-gynecological-oncology-esgo-congress</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/key-opinion-leader-kol-panel-to-discuss-acrivons-acr-368-endometrial-cancer-ec-trial-during-the-2026-european-society-of-gynecological-oncology-esgo-congress</guid>
<pubDate>Mon, 23 Feb 2026 05:00:00 GMT</pubDate>
<description>Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel</description>
</item>
<item>
<title>Acrivon Therapeutics Strengthens its Precision Medicine Therapeutics Capabilities with Launch of Internal CLIA-Certified Laboratory</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-strengthens-its-precision-medicine-therapeutics-capabilities-with-launch-of-internal-clia-certified-laboratory</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-strengthens-its-precision-medicine-therapeutics-capabilities-with-launch-of-internal-clia-certified-laboratory</guid>
<pubDate>Wed, 18 Feb 2026 05:00:00 GMT</pubDate>
<description>Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics</description>
</item>
<item>
<title>Acrivon Therapeutics Announces Late-Breaking Oral Presentation at Upcoming European Society of Gynecological Oncology (ESGO) Annual International Congress</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announces-breaking-oral-131100075</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announces-breaking-oral-131100075</guid>
<pubDate>Fri, 23 Jan 2026 13:11:00 GMT</pubDate>
<description>Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, will highlight company’s recent interim clinical data from the ongoing, registrational-intent Phase 2b study of ACR-368 in subjects with endometrial cancerWATERTOWN, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utiliz</description>
</item>
<item>
<title>Acrivon Therapeutics Announces Positive ACR-368 Phase 2b Endometrial Cancer Clinical Data with EU Expansion to Accelerate Enrollment, Initial ACR-2316 Clinical Data, and ACR-6840, its Next AP3-Enabled Development Candidate, Targeting CDK11</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announces-positive-acr-123000574</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announces-positive-acr-123000574</guid>
<pubDate>Thu, 08 Jan 2026 12:30:00 GMT</pubDate>
<description>Electronic data capture (EDC) extract from the ongoing ACR-368 registrational-intent Phase 2b monotherapy trial in OncoSignature-positive (BM+) subjects with endometrial cancer (EC) showed 39% overall response rate (ORR) and 44% in subjects with ≤2 prior lines of therapy* Analysis of data from all-comer subjects with serous subtype and ≤2 prior lines of therapy, a high unmet need population, showed a confirmed ORR (cORR) of 52%, and within BM+ subjects cORR was 67%, consistent with higher BM lev</description>
</item>
<item>
<title>Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announce-clinical-ongoing-123000168</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announce-clinical-ongoing-123000168</guid>
<pubDate>Tue, 06 Jan 2026 12:30:00 GMT</pubDate>
<description>Company to host conference call and webcast at 8:30 a.m. ET on Thursday, January 8, 2026WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Acrivon...</description>
</item>
<item>
<title>UPDATE -- Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates via Webcast</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announce-clinical-ongoing-143400587</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announce-clinical-ongoing-143400587</guid>
<pubDate>Wed, 17 Dec 2025 14:34:00 GMT</pubDate>
<description>WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical d</description>
</item>
<item>
<title>Acrivon Therapeutics to Announce Clinical Update on its Ongoing Phase 2b Studies and Planned Confirmatory Phase 3 Trial for ACR-368, Initial Clinical Data on ACR-2316, and Other AP3 Pipeline Updates</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announce-clinical-ongoing-123000995</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announce-clinical-ongoing-123000995</guid>
<pubDate>Wed, 17 Dec 2025 12:30:00 GMT</pubDate>
<description>WATERTOWN, Mass., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify global compound-specific, drug-regulated effects in the intact cell which is deployed for rational drug design and predictive clinical d</description>
</item>
<item>
<title>Acrivon Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reports-third-quarter-211000682</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reports-third-quarter-211000682</guid>
<pubDate>Thu, 13 Nov 2025 21:10:00 GMT</pubDate>
<description>Advancement of ACR-368 in registrational-intent Phase 2b trial for the treatment of patients with endometrial cancer Preparing for initial clinical data disclosure for ACR-2316 from the Phase 1 trial in AP3-prioritized solid tumor types Expanding power of Generative Phosphoproteomics AP3 supersedes conventional target-centric drug discovery, yielding differentiated compounds with desired pathway effects Cash, cash equivalents and marketable securities of $134.4 million as of September 30, 2025,</description>
</item>
<item>
<title>Acrivon Therapeutics Highlights its Powerful Generative Phosphoproteomics AP3 Platform with Compelling Preclinical Data for ACR-2316 with Three Presentations at the Upcoming AACR-NCI-EORTC International Conference</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-highlights-powerful-generative-201500301</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-highlights-powerful-generative-201500301</guid>
<pubDate>Wed, 22 Oct 2025 20:15:00 GMT</pubDate>
<description>AP3 Generative AI KaiSR model globally assesses drug effects on the entire intracellular protein signaling network for optimal drug design and precision medicine development Favorable ACR-2316 preclinical data, demonstrating its differentiated and superior pathway effects versus benchmark WEE1 and PKMYT1 inhibitors consistent with prior observations Company to report initial clinical data for ACR-2316 in AP3-predicted tumor types later this year; clinical activity and confirmed partial response</description>
</item>
<item>
<title>Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announces-inducement-grant-203000630</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-announces-inducement-grant-203000630</guid>
<pubDate>Wed, 01 Oct 2025 20:30:00 GMT</pubDate>
<description>WATERTOWN, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform designed to interpret and quantify compound specific, drug-regulated pathway activity levels inside the intact cell in an unbiased and actionable manner, today announced t</description>
</item>
<item>
<title>Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reports-second-quarter-201500371</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reports-second-quarter-201500371</guid>
<pubDate>Wed, 13 Aug 2025 20:15:00 GMT</pubDate>
<description>Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity -- ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types New paradigm for accelerated design and development of novel compounds, like ACR-2316, based on optimal intracellular pathway selectivity, uniquely enabled by AI-driven AP3 Generative Phosphoproteomics platform Cash, cash equivalents and marketab</description>
</item>
<item>
<title>Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reports-first-quarter-201000383</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reports-first-quarter-201000383</guid>
<pubDate>Wed, 14 May 2025 20:10:00 GMT</pubDate>
<description>Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-positive (BM+) patients, a majority of whom were refractory to last prior therapy, and cORR of 50% and mDOR >10 months (not yet reached) for BM+ patients who had relapsed on last prior therapy Three dose e</description>
</item>
<item>
<title>Acrivon Therapeutics to Reveal the Molecular Mechanisms Driving Strong Single-Agent Activity of ACR-2316, its AP3-Enabled Clinical Stage WEE1/PKMYT1 Inhibitor, at the AACR Annual Meeting 2025</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reveal-molecular-mechanisms-120000701</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-reveal-molecular-mechanisms-120000701</guid>
<pubDate>Fri, 25 Apr 2025 12:00:00 GMT</pubDate>
<description>Presentation to highlight how AP3 Generative Phosphoproteomic analyses uncover how ACR-2316 induces mitotic and replicative tumor cell death, and the mechanisms underlying its superior potency observed preclinically Phase 1 trial of ACR-2316 ahead of schedule with three dose-escalation cohorts completed; solid tumor shrinkage already observed at dose level three, well below the projected recommended Phase 2 dose WATERTOWN, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Ac</description>
</item>
<item>
<title>Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-appoints-world-renowned-200500383</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-appoints-world-renowned-200500383</guid>
<pubDate>Mon, 07 Apr 2025 20:05:00 GMT</pubDate>
<description>Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the past decades Will lead all clinical development -- including the ongoing ACR-368 Phase 2b registrational-intent trial in endometrial cancer towards regulatory submission and potential approval, and the ongoing ACR-2316 Phase 1 study in selected solid tumor types</description>
</item>
<item>
<title>Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-provides-program-updates-214400336</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-provides-program-updates-214400336</guid>
<pubDate>Thu, 27 Mar 2025 21:44:00 GMT</pubDate>
<description>Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive ACR-368 endometrial cancer data in OncoSignature-positive (BM+) patients with heavily pretreated aggressive tumors, and who had all progressed on prior anti-PD-1 and chemotherapy, with 35% confirmed overall response rate (cORR), which is >2-fold higher than last prior line of therapy (15%) In the</description>
</item>
<item>
<title>Acrivon Therapeutics to Host Corporate R&D Event to Provide AP3 Platform Capabilities and Clinical ACR-368 and ACR-2316 Program Updates</title>
<link>https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-host-corporate-r-120000156</link>
<guid isPermaLink="true">https://6ix.com/company/acrivon-therapeutics-inc-common-stock/news/acrivon-therapeutics-host-corporate-r-120000156</guid>
<pubDate>Wed, 19 Mar 2025 12:00:00 GMT</pubDate>
<description>Event to be held via webcast on March 25, 2025 at 4:00 p.m. ET To highlight differentiated drug discovery capabilities with its Generative Phosphoproteomics AP3 platform and program updates from the Phase 2b study of ACR-368 and Phase 1 study of ACR-2316 WATERTOWN, Mass., March 19, 2025 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage precision medicine company utilizing its Acrivon Predictive Precision Proteomics (AP3) platfor</description>
</item>
</channel>
</rss>